Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Co-Diagnostics, Inc. - Common Stock (NQ: CODX )

0.4843 +0.0067 (+1.40%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Co-Diagnostics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Penny Stock Co-Diagnostics Withdraws FDA Application For COVID-19 Test, Plans To Submit Enhanced Version
Co-Diagnostics plans to submit an enhanced COVID-19 test for FDA clearance, addressing stability concerns and integrating platform advancements. 
Via Benzinga
Exposures COVID-19 Product Safety
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
CODX Stock Earnings: Co-Diagnostics Beats EPS, Beats Revenue for Q2 2024
CODX stock results show that Co-Diagnostics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Peering Into Co-Diagnostics's Recent Short Interest
Via Benzinga
Co-Diagnostics: Q4 Earnings Insights
Via Benzinga
Earnings Preview: Co-Diagnostics
Via Benzinga
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
CODX Stock Earnings: Co-Diagnostics Misses EPS, Misses Revenue for Q1 2024
CODX stock results show that Co-Diagnostics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
CODX Stock Earnings: Co-Diagnostics Misses EPS, Misses Revenue for Q4 2023
CODX stock results show that Co-Diagnostics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Preview: Co-Diagnostics's Earnings
Via Benzinga
Co-Diagnostics Earnings Perspective: Return On Invested Capital
Via Benzinga
Preview: Co-Diagnostics's Earnings
Via Benzinga
Earnings Scheduled For March 14, 2024
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter. 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year
In response to the escalating spread of the virus nationwide, the Biden administration declared that it would recommence offering free at-home COVID tests to American households starting next Monday. 
Via Benzinga
Exposures COVID-19
7 Doomed Growth Stocks Destined for Disaster
Investing in growth stocks can be very expensive. Save yourself some time and money by avoiding these doomed growth stocks to sell. 
Via InvestorPlace
Spectrum Brands, Sanmina And 3 Stocks To Watch Heading Into Friday
With US stock futures trading higher this morning on Friday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 20, 2023
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Co-Diagnostics's Earnings Outlook
Co-Diagnostics (NASDAQ:CODX) is set to give its latest quarterly earnings report on Thursday, 2022-11-10. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests
Via Benzinga
7 Vaccine Stocks to Sell ASAP Now That the ‘Pandemic’s Over’
Investors have seven widely-followed vaccine stocks to sell now, after the world decided the pandemic is over. 
Via InvestorPlace
COVID-19 Complacency Pushes Identification Of New Variants To Back Seat, WHO Warns
The World Health Organization (WHO) warned that it struggles to identify and 
Via Benzinga
Co-Diagnostics's Return On Capital Employed Overview
Benzinga Pro data, Co-Diagnostics (NASDAQ:CODX) reported Q2 sales of $5.02 million. Earnings fell to a loss of $2.69 million, resulting in a 122.93% decrease from last quarter. 
Via Benzinga
No More Free COVID-19 At-Home Tests, Federal Government Says
CNBC reported that the federal government is set to suspend its offer of free at-home COVID-19 tests by Friday, September 2, without congressional au 
Via Benzinga
Mizuho Increases PT On ON Semiconductor, Charter Communications Price Target Cut By 37%
Atlantic Equities lowered the price target on Charter Communications, Inc. (NASDAQ: CHTR) from $755 to $477. Charter Communications shares fell 1.7% to $470.00 in pre-market trading. 
Via Benzinga
This Analyst Boosts Price Target On Dillard's; Also Check Out Some Other Big PT Changes
JP Morgan raised the price target for Dillard's, Inc. (NYSE: DDS) from $210 to $298. Dillard's shares rose 0.9% to $304.42 in pre-market trading. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's trading, 62 companies set new 52-week lows. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.